India  

Covaxin has overall vaccine efficacy of 77.8%, claims Bharat Biotech in results from Phase 3 trials

Zee News Saturday, 3 July 2021
Covaxin showed 65.2% protection against the Delta variant (B.1.617.2) of COVID-19. 
0
shares
ShareTweetSavePostSend
 
Video Credit: Oneindia - Published
News video: Covaxin is 77.8% effective against Covid-19, claims Bharat Biotech: Details | Oneindia News

Covaxin is 77.8% effective against Covid-19, claims Bharat Biotech: Details | Oneindia News 02:13

Covaxin maker Bharat Biotech has claimed that the vaccine is 77.8% effective overall against Covid-19 after analysing results for its phase 3 trials. Bharat Biotech also claimed that Covaxin provides 65.2% protection against the Delta strain, which was a main driving factor behind India's second wave...

You Might Like


Related news from verified sources

WHO Chief Scientist Dr Swaminathan says phase-3 trials of Covaxin look good, Bharat Biotech awaits approval

A few days ago, Bharat Biotech had released the phase 3 clinical trial results of Covaxin after evaluating 130 symptomatic COVID-19 cases.
DNA

Bharat Biotech says vaccine 93.4% effective against severe Covid-19

Phase-III trials of Covaxin, made by Hyderabad's Bharat Biotech showed it was 93.4% effective against severe symptomatic Covid-19, the firm said on Saturday. The...
IndiaTimes

Brazil's Anvisa provisionally suspends authorisation for exceptional import of 4 million Covaxin doses

After closing the emergency use authorisation (EUA) and Phase-3 clinical trials requests for Bharat Biotech’s Covaxin, Brazil’s health regulator Anvisa...
IndiaTimes